# Castle Biosciences Incorporated

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/castle-biosciences

- Industry: Biotechnology
- Headquarters: Friendswood, US
- Website: www.castlebiosciences.com
- Total disclosed funding: $19M
- Latest round: Series F (Jul 27, 2015)
- Investors on record: 5

## About

Founded in 2008 and based in Texas, US, Castle Biosciences Incorporated is a molecular diagnostics company focused on developing molecular and prognostic tests for cancer. The company develops a genomic test called DecisionDx-Melanoma for cutaneous melanoma to identify metastatic risk in stages 1 and 2. They also develop a test called DecisionDx-UM to measure the the activity or gene expression of a uveal melanoma to develop a management plan. In July 2019, Castle Biosciences Incorporated raised  KRW  23 billion in venture funding from new investors Stonebridge Capital and Highland Capital Management Korea.

## Funding rounds

- Series F, Jul 27, 2015, $12M — Industry Ventures
- Series E, Aug 13, 2014, $7.5M — Sofinnova Investments, Mountain Group Partners, Longfellow Venture Partners, HealthQuest Capital

## Investors

- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series E
- Mountain Group Partners (https://capitalatlas.ai/funds/mountain-group-partners) — Series E
- Longfellow Venture Partners — Series E
- HealthQuest Capital (https://capitalatlas.ai/funds/healthquest-capital) — Series E
- Industry Ventures (https://capitalatlas.ai/funds/industry-ventures) — Series F